MAPLIRPACEPT
UNII 44D51T6SZH

Substance Identification & Data

This profile provides standardized clinical and technical data for Maplirpacept, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 44D51T6SZH.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2631667-06-4 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

44D51T6SZH

CAS Registry Number

2631667-06-4

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

MAPLIRPACEPT

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C150756

National Cancer Institute reference terminology for clinical and research data.

INN ID

12295

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

LM-237

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Maplirpacept. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

MAPLIRPACEPT

Common Names & Synonyms

1-118-SIGNAL REGULATORY PROTEIN .ALPHA. (HUMAN) FUSION PROTEIN WITH IMMUNOGLOBULIN G4 (128-PROLINE) (HUMAN .GAMMA.4-CHAIN C REGION C-TERMINAL FRAGMENT), DIMER

HUMAN SIGNAL-REGULATORY PROTEIN ALPHA (SIRP.ALPHA., TYROSINE-PROTEIN PHOSPHATASE NON-RECEPTOR TYPE SUBSTRATE 1, INHIBITORY RECEPTOR SHPS-1), NATURAL (L14>S, T20>S, T22>I, R24>H, A27>V, G45>A, D65>E, L66>S, N70>E, R77>S, G79>S, D101>DEL, V102>T101)- VARIANT, N-TERMINAL (1-118)-FRAGMENT (BINDING DOMAIN FOR CD47 (INHIBITOR OF PHAGOCYTOSIS BY MACROPHAGES)), FUSED TO A C-TERMINAL FC FRAGMENT OF HUMAN IMMUNOGLOBULIN G4 (119-347), IGHG4*01; HINGE 119- 130 (S128>P)-VARIANT; CH2 131-240; CH3 241-345; CHS 346-347; DIMER (126-126':129-129')-BISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, GLYCOFORM ALFA

MAPLIRPACEPT [INN]

MAPLIRPACEPT [USAN]

MAPLIRPACEPT [WHO-DD]

SIRPA-IGG4-FC FUSION PROTEIN TTI-622